Milical

Quick links to important sections

Milical

Method of action: Vitamins

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milical

Property Description
Active ingredient Calcium Citrate, Dihydrotachysterol (DHT)
Form Oral formulation (Tablet, Capsule, Liquid)
Pharmacological class Calcium and Phosphate Metabolism Regulator, Vitamin D Analog
Common use Correction of mineral deficiencies, support for bone mineralisation
Origin Combination of Essential Mineral and Synthetic Analog

Milical is a combination medication classified primarily as a Calcium and Phosphate Metabolism Regulator and a Vitamin D Analog, formulated for the oral route administration. It is an oral formulation, available in presentations such as a Tablet, Capsule, or Oral liquid, and is designed to support the body's essential mineral balance. This designation highlights its role as an active agent intended to both supply minerals and regulate their physiological utilization, setting it apart from simple dietary supplements.


What Type of Medicine is Milical?

Milical is a combination product that belongs to the pharmacological class of agents supporting bone mineralisation and mineral homeostasis. Its regulatory function focuses on the systemic management of calcium, a mineral essential for bone structure and general health. Adequate calcium intake is recognized for maintaining healthy, dense bones. Its classification as a Calcium and Phosphate Metabolism Regulator underscores its direct function as a calcium regulator within the systemic environment, supported by the synergistic effects of mineral supplementation and regulatory analogs.


Composition: Calcium Citrate and Dihydrotachysterol

The core active ingredients in Milical are Calcium Citrate and Dihydrotachysterol (DHT). Calcium Citrate serves as a highly bioavailable source of Elemental Calcium for skeletal structure and nerve function, providing the calcium necessary for maintaining healthy bones. The key regulatory component is Dihydrotachysterol, a unique synthetic analog of Vitamin D. DHT is engineered to enhance the absorption of both Calcium and Phosphate within the intestinal tract. This chemical composition provides therapeutic support beyond that of simple mineral replacement, making the formulation suitable for patients who require enhanced mineral absorption or targeted Vitamin D Analog activity.


What is the General Purpose of Milical?

The general purpose of Milical is to prevent or correct deficiencies in Calcium and Vitamin D, a common scenario, for example, in postmenopausal women or the elderly requiring support for bone density. By reliably elevating and maintaining the systemic concentration of these critical minerals, it supports the natural process of bone mineralisation. This action helps address mineral imbalances, working to stabilize the necessary environment for the maintenance of healthy, dense bones and overall mineral balance.

Regulatory References

  1. MedlinePlus

What side effects are possible with Milical?

Possible Side Effects and Safety Information

The safety profile of Milical, which contains Calcium Citrate and the Vitamin D analog Dihydrotachysterol (DHT), is centered on its effects as a Calcium and Phosphate Metabolism Regulator, as described in official government regulatory documents.

Adverse Reactions and Systemic Classification

The most significant and officially classified safety concern is the regulation of calcium levels. Hypercalcemia (elevated blood calcium) and Hypercalciuria (excessive urinary calcium) are documented as uncommon adverse reactions.

Adverse effects are grouped into System-Organ Classes, which include Metabolism and Nutrition Disorders (e.g., hypercalcemia) and Gastrointestinal Disorders, where reactions such as constipation and nausea may occur.

Serious Adverse Reactions

Regulatory documentation highlights serious, though less frequent, risks, primarily linked to sustained high calcium levels. These include the potential for Severe Hypercalcemia, which can lead to cardiac and neurological complications, and Nephrocalcinosis (calcification of the kidneys), which may result in irreversible renal damage.

Safety Patterns and Restrictions

Official labels note that the risk of serious renal damage is associated with long-term exposure. The effects of the Dihydrotachysterol component can persist for two or more months after treatment is stopped. Milical is formally contraindicated in patients with pre-existing Hypercalcemia or those with established Severe Renal Insufficiency or Nephrocalcinosis. Specific caution and monitoring are required for patients with renal impairment or those who are immobilized.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Milical


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Overdose symptoms are consistent with severe or protracted hypercalcemia, resulting from ingestion of quantities exceeding the recommended dose.
Physiological systems affected The primary affected systems include the renal, cardiovascular, gastrointestinal, and neurological systems.
Dose-related or exposure-related factors Ingestion of quantities exceeding the recommended dose leads to accumulation of the active agents, resulting in progressive hypercalcemia and subsequent toxicity.
Population-specific overdose notes Infants exposed to the drug should be monitored for signs and symptoms of hypercalcemia.
Emergency-response statements Contact emergency medical services or the national Poison Control Center immediately.
When immediate medical help is required Immediate medical attention is required for severe or life-threatening symptoms, particularly signs of hypercalcemic crisis, such as collapse, seizures, or loss of consciousness.

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification Toxicity may progress from mild hypercalcemia to a potentially life-threatening hypercalcemic crisis.
Regulatory basis Information derived from the overdose and toxicology sections of government-authorized prescribing information.
Overdose-context constraints Treatment is supportive and symptomatic; no specific antidote is known or documented in the regulatory labeling.

Resulting Overdose Structure

Official overdose statements:

  • Initial signs may include headache, fatigue, nausea, anorexia, and increased urination (polyuria) and thirst (polydipsia).
  • Severe overdose risks cardiac arrhythmias, hypertension, renal insufficiency, and potential death due to cardiorenal failure.
  • Management protocols require mandatory drug withdrawal, hydration, and, for severe cases, clinical interventions such as intravenous saline and loop diuretics.
  • Monitoring requirements necessitate frequent measurement of serum calcium levels until normalization and observation of vital signs and electrocardiogram (ECG).

Connection to the overall overdose profile Regulatory documents define the Milical overdose profile by establishing hypercalcemia as the toxic mechanism leading to severe outcomes like cardiorenal failure and neurological crisis. This severity dictates the mandatory emergency intervention triggers, which explicitly state the need to seek immediate medical help for specific life-threatening symptoms.

Therapeutic Uses of Milical

What Milical Treats: Main Uses and Benefits

The therapeutic actions of Milical may be applied in providing supportive relief and management for conditions where temporary physiological imbalance may affect stability. Milical is considered relevant in contexts marked by increased discomfort or tension, commonly used for conditions involving episodic or fluctuating manifestations that require short-term symptomatic assistance. Addressing underlying deficiencies and related conditions may be relevant for supporting general systemic comfort.

Management of Symptoms and Clinical Scenarios

The medication is useful in scenarios where symptoms escalate temporarily, such as in managing distressing symptoms and addressing symptom clusters that interfere with daily comfort. This use may assist with supporting functional stability and contributes to easing the overall symptom load during symptomatic phases. Milical is commonly applied during phases when symptoms become more noticeable, offering supportive relief that may help patients cope more steadily with difficult episodes.

Indications and Benefits

Milical is used in situations involving certain distressing symptoms, generally within conditions where functional stability may become affected. It may assist with easing the overall symptom load in conditions characterized by periods of heightened symptoms.

Quick Fact: Symptomatic Relief Support

Eligibility and Restrictions for Use

Eligibility Scope and Restrictions

Milical, containing Calcium Citrate and Dihydrotachysterol (a Vitamin D Analog), is primarily intended for adults for the management of mineral deficiencies. The official regulatory profile defines strict conditions and patient groups for whom use is prohibited or restricted.


Contraindicated Populations
Patients with Hypercalcemia (high blood calcium levels)
Patients with Hypervitaminosis D (excessive Vitamin D)
Patients with Severe Renal Impairment (severe kidney disease)
Patients with a history of Nephrolithiasis (kidney stones)
Patients with Hypersensitivity to the active substances or excipients

Restricted or Condition-Specific Use
Children and Adolescents: Use is generally not recommended or contraindicated in those under 18 years of age due to the potent nature of the Vitamin D component.
Pregnancy: Use is advised only if the potential benefit clearly outweighs the potential risk to the fetus, as the safety profile is not fully established.
Lactation: Use is generally not recommended by regulatory bodies, as metabolites of the Vitamin D analog are excreted in breast milk.
Sarcoidosis: Use requires caution and close monitoring, as patients with this condition may exhibit increased sensitivity to Vitamin D analogs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail two main interaction domains for Milical (Calcium Citrate and Dihydrotachysterol): the risk of mineral overload and the reduction of co-administered drug exposure. The combination with Eltrombopag is a contraindicated combination due to calcium's severe inhibition of Eltrombopag absorption, requiring a minimum of four hours separation when use of calcium is unavoidable.

Classification Interacting Agents
Pharmacodynamic Risk Cardiac Glycosides (e.g., Digoxin), Thiazide Diuretics, Other Vitamin D Analogs
Absorption Interference Oral Tetracycline and Fluoroquinolone Antibiotics, Thyroid Hormones (e.g., Levothyroxine), Oral Bisphosphonates

Co-administration with Thiazide Diuretics or other Vitamin D Analogs increases the risk of Hypercalcemia due to additive effects on calcium levels. The combination with Cardiac Glycosides increases the risk of cardiotoxicity and arrhythmias. Bile Acid Sequestrants (e.g., Cholestyramine) reduce the absorption of Dihydrotachysterol. Interactions with food, such as consumption of Grapefruit Juice, may alter Dihydrotachysterol plasma concentrations, and foods high in oxalic or phytic acid may decrease calcium absorption. Mandatory administration spacing requirements are specified to mitigate the chelating effect of calcium on various oral medications, thereby preserving their therapeutic effectiveness. The official label notes that interaction severity may be heightened in patients with renal or hepatic dysfunction.

Mechanism of Action

Milical, as a source of calcium citrate, functions as an extracellular ion substrate. The active calcium ion ( Ca^2+) is absorbed primarily across the intestinal epithelium via both paracellular diffusion and transcellular transport mediated by proteins like TRPV6. Upon entering the systemic circulation, Ca^2+ modulates system-level physiological processes.

In the parathyroid gland, Ca^2+ acts as an agonist at the Calcium-Sensing Receptor ( CaSR), a G-protein coupled receptor. Activation of CaSR on parathyroid cells, primarily by coupling to the G q protein, triggers the intracellular cascade involving phospholipase C ( PLC), which generates inositol trisphosphate ( IP3) and diacylglycerol ( DAG). This signaling cascade subsequently leads to an acute reduction in the secretion of parathyroid hormone ( PTH). The resulting decrease in PTH concentration modulates bone remodeling by reducing osteoclast activity and promotes Ca^2+ deposition into the skeletal structure. The reduced PTH also downregulates renal TRPV5 channels, increasing urinary Ca^2+ excretion.

Dosage and Administration Information

General Principles of Administration

Milical is exclusively designed for oral administration, available in tablet, capsule, and oral liquid forms. The dosage regimen for adults is generally structured for long-term continuous administration to support sustained mineral homeostasis. The typical daily intake ranges from 500 mg to 1000 mg of elemental calcium equivalent, combined with the prescribed Dihydrotachysterol (DHT) dose. The total elemental calcium intake from all sources is generally recommended not to exceed 1500 mg per day.


Frequency and Contextual Use

The medicine is commonly taken once daily or may be administered in two divided doses to optimize mineral absorption. Standard instructions suggest that the oral forms be taken with food and a full glass of water. For the oral liquid formulation, accurate measurement with a calibrated device is a required procedural step to ensure the precise dosing of the DHT component. Patients are instructed not to exceed the established maximum daily dosage.


Population-Specific Considerations

Regarding specific populations, clinical guidelines suggest that patients with renal impairment require close monitoring of serum calcium and phosphate levels, often necessitating a reduction or modification of the DHT component's dose. While there is no mandatory adjustment for older adults based on age alone, individual titration may be warranted based on their renal function. Treatment continuation and dose adjustments are dependent on periodic clinical and laboratory assessments.

Recent Clinical Evidence

Research evidence / Overview of Studies for Milical

This overview summarizes the scientific evidence, drawn from authoritative governmental and peer-reviewed sources, that has explored the combination of Calcium Citrate and Dihydrotachysterol (DHT).


Evidence for Use in Correcting Mineral Deficiencies

Research has explored this combination in populations evaluated for mineral deficiencies, such as those characterized by low calcium levels (hypocalcemia) or inadequate Vitamin D-related activity. Researchers conducted Randomized Controlled Trials (RCTs) and systematic reviews. Studies specifically monitored key biomarker outcomes related to mineral status, such as the achievement and maintenance of specified target ranges for serum calcium and related biomarkers. Research has examined the Dihydrotachysterol analog, which relates to intestinal calcium absorption, particularly in conditions where the body has difficulty processing standard Vitamin D.

Findings describe patterns observed in the studies where the combination was associated with changes measured during the study period. Despite the established role of the components, comparative evidence is lacking regarding the direct head-to-head performance of this specific combination versus other forms of calcium and active Vitamin D analogs. The long-term effects are not fully established in studies of broader populations.


Evidence Supporting Bone Mineralisation

Studies exploring support for bone mineralisation typically involve Systematic Reviews and Meta-analyses that pool data from numerous long-term RCTs of calcium and Vitamin D combinations. These research efforts primarily focused on older populations, particularly postmenopausal women, and studies explored outcomes related to Bone Mineral Density (BMD) at sites like the hip and spine, as well as fracture incidence over multi-year periods.

Studies reported changes in Bone Mineral Density (BMD) in patients receiving calcium and Vitamin D combinations. However, research exploring the effect of supplementation alone on major fracture incidence has been mixed and heterogeneous across various studies and populations. Findings were mixed regarding fracture reduction across all populations and study designs, reflecting that evidence quality varies across studies.


What Is Still Uncertain About the Research

The research evidence provides context but does not determine whether an individual will respond similarly. Comparative evidence is lacking for a direct comparison of this specific combination against many alternatives in broader settings. Study heterogeneity is a persistent issue in the research, where variability in patient diets, baseline vitamin D status, and study methodology makes it difficult to draw firm conclusions. Long-term effects are not fully established for the specific DHT component in the context of general, non-metabolically impaired bone health support.

Frequently Asked Questions (FAQ)

Common questions about Milical (FAQ)


Q: How long does it usually take to feel a difference after starting Milical?

A: Official information about Dihydrotachysterol (DHT), one of the medicine’s active ingredients, indicates it has a relatively rapid onset of action. This is based on pharmacokinetic data showing that the component begins to act within approximately 2 hours of administration.


Q: Is it safe to use for older adults (seniors)?

A: Official information does not require mandatory dose adjustment for older adults based on age alone. However, regulatory documents note that monitoring of kidney function (renal function) is a required consideration during treatment, as eligibility may depend on the patient's renal status.


Q: Can I drink alcohol while taking Milical?

A: Official safety information notes a reported alcohol/food/lifestyle interaction classified as moderate involving the Dihydrotachysterol component. Additionally, heavy alcohol consumption is known to potentially reduce the body’s ability to properly absorb calcium, which is relevant to the medicine's function.


Q: Why does the official document list so many potential drug interactions for Milical?

A: The extensive list of potential interactions is primarily related to the actions of the calcium component. Calcium has the ability to reduce the absorption of certain other oral medications through a chemical process called chelation, which can lessen the effectiveness of those other medicines.


Q: What is the general safety classification of Milical for pregnant women (e.g., Category B or C)?

A: Dihydrotachysterol, one of the active ingredients, has historically been assigned to the Pregnancy Category C by the U.S. FDA. Regulatory documents state that use during pregnancy is restricted to cases where the potential benefit is considered to outweigh the potential risk.


Q: Can I take Milical if I'm already taking a blood pressure medicine?

A: Official regulatory documents specifically note an interaction risk with Thiazide Diuretics, which is a common type of medicine used for high blood pressure. This interaction occurs due to an additive risk of developing Hypercalcemia (elevated blood calcium levels) when the medicines are used in combination.


Q: Does Milical make you tired or affect your sleep?

A: Tiredness (fatigue) or drowsiness is described in official safety documents. This feeling is listed as an early symptom that may be associated with Hypercalcemia (elevated blood calcium), which is a key potential adverse reaction of the medicine.


Q: How often do people typically need to follow up with a doctor while on Milical?

A: Official documents require periodic clinical and laboratory assessments throughout the treatment period. This includes regular monitoring of serum calcium and phosphate levels, though the regulatory documents do not specify a single fixed schedule for all patients.


Q: Are there any known interactions between Milical and common supplements like vitamins or herbal products?

A: The official label advises caution, noting that the medicine may interact with other supplements containing Vitamin D or calcium. For this reason, official documents caution against their use unless specifically directed by a healthcare professional.


Q: Is it normal to feel a change in appetite when using Milical?

A: Loss of appetite is described in official safety documents as a possible early symptom associated with Hypercalcemia (elevated blood calcium levels). This is a potential adverse reaction listed in the official safety profile for the medicine.


Q: Is there a patient information leaflet (PIL) available for Milical online?

A: Yes, official documents for the product, such as the Patient Information Leaflet (PIL) or the Medication Guide, are publicly available. These materials are provided online via government and regulatory agency websites and contain full prescribing and safety details.


Q: How is Milical different from a vitamin or mineral supplement?

A: Milical is a combination product officially classified as a Calcium and Phosphate Metabolism Regulator. It contains Dihydrotachysterol, a synthetic Vitamin D analog, which gives it a more potent and active regulatory function over mineral balance than a simple dietary supplement alone.


Q: Are skin rashes a possible side effect of Milical?

A: While skin rash is not listed as a common adverse reaction, official documents list Hypersensitivity (allergic reactions) as a contraindication. Hypersensitivity reactions may involve skin symptoms such as hives or swelling.


Q: Are there specific food restrictions mentioned for Milical?

A: Yes, official warnings include specific cautions for certain food items. These include grapefruit juice and foods high in oxalic or phytic acid because of their potential to alter the medicine's absorption or effects in the body.


Q: How is Milical eliminated from the body?

A: The Dihydrotachysterol component is processed (metabolized) by enzymes in the liver and is then regulated by the kidneys and other tissues. This process describes how the component is systematically eliminated from the body.


Q: Why do some people need to have blood tests done while on Milical?

A: Blood tests are a required step to closely monitor a person's levels of serum calcium and phosphate. This monitoring helps ensure that the prescribed dose is appropriate and helps prevent the risk of developing Hypercalcemia (elevated blood calcium).


Q: Does Milical interact with common painkillers like ibuprofen or acetaminophen?

A: Official regulatory documents for this medicine do not list specific interactions with common over-the-counter painkillers such as Ibuprofen or acetaminophen.


Q: Is there a specific time of day that Milical is meant to be taken?

A: Official instructions require the medicine to be taken with food for optimal absorption. However, the regulatory documents do not specify a mandatory time of day, such as only morning or only evening.


Q: Is Milical a habit-forming or controlled substance?

A: According to regulatory classification, Milical is not listed as a controlled substance under the U.S. Controlled Substances Act (CSA) and is not considered a habit-forming medicine.


Q: Are there any warnings about sunlight exposure while using Milical?

A: The official safety profile for the Dihydrotachysterol component cautions that high levels of Vitamin D may increase the risk of elevated calcium. Official guidelines note that matters of excessive exposure should be considered with a healthcare provider.


Q: What are the alternatives to Milical mentioned in medical literature?

A: Research has, at times, compared Dihydrotachysterol to other types of Vitamin D analogs, such as Calcitriol, or other forms of calcium supplementation in specific patient groups. The regulatory label notes that comparative evidence is often lacking in broader settings.


Q: Are there any long-term studies on using Milical?

A: While the regulatory label notes that the long-term effects are not fully established in the general population, there is published medical literature that has examined the long-term use of Dihydrotachysterol, particularly in patients with specific chronic medical conditions.

How should Milical be stored and disposed of?

Storage and Disposal Requirements for Milical

Milical, which contains Calcium Citrate and a Vitamin D Analog, must be stored according to regulatory specifications to ensure product stability.

Required Storage Conditions

The product must be stored at Controlled Room Temperature (typically below 30 C) and should not be frozen. It is essential to keep the medicine in its original container, tightly closed, and protected from direct sunlight, moisture, and heat. A critical safety requirement is to store Milical out of the sight and reach of children.


Disposal

Disposal of any unused or expired Milical must be done in accordance with local regulations.

The preferred method is utilizing a community drug take-back program. If no program is available, the product should be mixed with an undesirable substance and placed in a sealed container before disposal in household trash, avoiding discharge into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Milical found in:

A-Z Index: